Printed from Voxsanity (voxsanity.com.au) — NCT06682156 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Myeloma
Myeloma Trial, Recruiting
NCT06682156
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older
- People who have been diagnosed with multiple myeloma according to standard international diagnostic guidelines
- People who have received only one previous round of treatment for multiple myeloma, and that treatment was a three-drug combination including bortezomib plus dexamethasone, paired with one of the following: lenalidomide, thalidomide, cyclophosphamide, or adriamycin
- People whose ability to carry out daily activities is not severely limited — rated as 0, 1, or 2 on a standard activity scale used by doctors (confirm with trial site)
- People who experienced side effects from bortezomib serious enough that their doctor reduced the dose or stopped the drug — including certain levels of nerve pain, liver problems, diarrhoea, or other significant non-blood-related side effects (confirm with trial site)
- People who are willing to give written consent to take part in the study
Who may not be able to join:
- People who are currently taking part in another clinical trial that involves a treatment intervention (trials that only observe without giving treatment may be acceptable — confirm with trial site)
- People who have previously been treated with carfilzomib, or who have taken part in any study involving carfilzomib
- People whose multiple myeloma has also developed into a related blood cancer called plasma cell leukaemia
- People who have not yet fully recovered from the side effects of their previous chemotherapy (confirm with trial site)
- People who had a different cancer diagnosed before their multiple myeloma diagnosis — with some exceptions for certain skin cancers or very early-stage cancers that were treated successfully and have a low chance of returning
- People who have an active infection, active hepatitis B or C, or a known positive HIV test result
- People with uncontrolled heart problems, including uncontrolled high blood pressure, certain irregular heart rhythms, severe heart failure, unstable chest pain, a heart attack in the past three months, or poor heart pumping function on an ultrasound
- People with significant lung conditions such as moderate-to-severe chronic obstructive pulmonary disease (COPD), ongoing asthma, or asthma within the past two years (mild or well-controlled asthma may be assessed individually — confirm with trial site)
- People who would be unable to follow the requirements of the study
- People who have a known allergy to carfilzomib or any of its ingredients
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Not Applicable
Sponsor
The First Affiliated Hospital of Soochow University
Registry
ClinicalTrials.gov
Start date
10 September 2024
Est. completion
31 March 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Outcome of peripheral neuropathy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.